SECOND AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA ANTIBIOTICS, INC.Technology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Second Amendment to the Technology Transfer and Supply Agreement (“2nd Amendment”) is made and effective as of 17th day of October, 2014 (“ Amendment Effective Date”), by and between Hospira Worldwide, Inc., (“Hospira”), and Theravance Biopharma Antibiotics, Inc. (“Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this 2nd Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).
FIRST AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE, INC.Technology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This First Amendment to the Technology Transfer and Supply Agreement (“Amendment”) is made and effective as of May 16, 2013 (“Amendment Effective Date”), by and between Hospira Worldwide, Inc., (“Hospira”), and Theravance, Inc. (“Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).
THIRD AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA IRELAND LIMITEDTechnology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Third Amendment to the Technology Transfer and Supply Agreement (“3rd Amendment”) is made and effective as of April 14, 2016 (“Amendment Effective Date”), by and between Hospira Worldwide, Inc., (“Hospira”), and Theravance Biopharma Ireland Limited, the successor in interest to Theravance Biopharma Antibiotics, Inc. (“Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this 3rd Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).
FOURTH AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between PFIZER, INC. and THERAVANCE BIOPHARMA IRELAND LIMITEDTechnology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Fourth Amendment to the Technology Transfer and Supply Agreement (“4th Amendment”) is made and effective as of September 29, 2016 (“Amendment Effective Date”), by and between the Pfizer CentreOne group of Pfizer, Inc., (as successor in interest to the One 2 One group of Hospira Worldwide, Inc., hereafter “Pfizer”), and Theravance Biopharma Ireland Limited (as successor in interest to Theravance Biopharma Antibiotics, Inc., hereafter, “Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this 4th Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein). References to numbered articles and sections cited herein refer to specific articles or sections of the Agreement.
